Financial Gravity Wealth Inc. purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 254 shares of the medical research company’s stock, valued at approximately $70,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Truvestments Capital LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $29,000. Capital Financial Planning LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $27,000. Hanson McClain Inc. increased its position in shares of Thermo Fisher Scientific by 263.9% during the fourth quarter. Hanson McClain Inc. now owns 131 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares in the last quarter. CX Institutional bought a new stake in Thermo Fisher Scientific in the 1st quarter worth approximately $36,000. Finally, Capital Investment Advisory Services LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter worth approximately $35,000. 88.66% of the stock is owned by institutional investors.
A number of equities research analysts have commented on the stock. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $264.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 30th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $310.00 target price for the company in a research report on Tuesday, April 9th. Deutsche Bank lifted their target price on shares of Thermo Fisher Scientific from $275.00 to $300.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. BTIG Research lifted their target price on shares of Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a research report on Tuesday, March 26th. Finally, Bank of America reaffirmed a “buy” rating and issued a $300.00 target price (up previously from $285.00) on shares of Thermo Fisher Scientific in a research report on Tuesday, April 16th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and a consensus price target of $289.92.
In other news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction on Monday, March 4th. The shares were sold at an average price of $266.00, for a total transaction of $665,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Peter E. Hornstra sold 5,920 shares of Thermo Fisher Scientific stock in a transaction on Friday, February 15th. The stock was sold at an average price of $250.00, for a total transaction of $1,480,000.00. Following the transaction, the chief accounting officer now owns 17,057 shares in the company, valued at approximately $4,264,250. The disclosure for this sale can be found here. Insiders have sold a total of 36,927 shares of company stock worth $9,388,124 in the last quarter. Corporate insiders own 0.49% of the company’s stock.
NYSE:TMO opened at $259.78 on Monday. The company has a quick ratio of 1.24, a current ratio of 1.73 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 12 month low of $202.83 and a 12 month high of $282.98. The company has a market capitalization of $103.65 billion, a price-to-earnings ratio of 23.36, a P/E/G ratio of 1.71 and a beta of 1.13.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 30th. The medical research company reported $3.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.06. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.26 billion. Thermo Fisher Scientific had a net margin of 12.06% and a return on equity of 16.86%. The company’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the company posted $2.79 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 12.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 16th. Stockholders of record on Friday, March 15th were paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.
WARNING: This story was originally reported by Highlight Press and is owned by of Highlight Press. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://highlightpress.com/2019/04/22/financial-gravity-wealth-inc-purchases-new-stake-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: What is Cost of Debt?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.